Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
Researchers at University of Louvain publish new data on immunization
September 24th, 2008
In this recent report, researchers in Brussels, Belgium conducted a study "To protect a naive global population against pandemic influenza, pandemic vaccines should be effective at low antigen doses, because of limited manufacturing capacity. In a multicenter, randomized, blind-observer phase 1 trial, groups of 50 healthy young adults received 2 doses, 21 days apart, of influenza A/Vietnam/1194/2004 NIBRG-14 (H5N1) vaccine containing 1.9, 3.8, 7.5 or 15 mu g of hemagglutinin with oil-in-water emulsion adjuvant or 7.5 mu g of hemagglutinin without adjuvant." "Safety was monitored to day 42. Homologous hemagglutination-inhibition ( HI) and microneutralization titers were...
Source: Vaccine Weekly (2008-09-24)
|
